|
| 37814424 | Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR. | Pediatr Blood Cancer | 2024 |
| 37814424 | Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR. | Pediatr Blood Cancer | 2024 |
| 37880926 | Radiotherapy and long-term sequelae in pediatric patients with parameningeal rhabdomyosarcoma: Results of two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. | Pediatr Blood Cancer | 2024 |
| 37880926 | Radiotherapy and long-term sequelae in pediatric patients with parameningeal rhabdomyosarcoma: Results of two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. | Pediatr Blood Cancer | 2024 |
| 35882450 | The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. | Neuro Oncol | 2023 |
| 35882450 | The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. | Neuro Oncol | 2023 |
| 37856763 | Inflammatory Myofibroblastic Tumor With <i>ROS1</i> Gene Fusions in Children and Young Adolescents. | JCO Precis Oncol | 2023 |
| 37932833 | Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. | Acta Neuropathol Commun | 2023 |
| 37287693 | A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial <i>ZFTA-</i>fused ependymoma. | Neurooncol Adv | 2023 |
| 37085539 | 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma. | Nat Commun | 2023 |
| 36964296 | Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. | NPJ Precis Oncol | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 37066598 | Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). | Pediatr Blood Cancer | 2023 |
| 37441736 | Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. | Clin Pharmacol Ther | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37246777 | Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study. | Neuro Oncol | 2023 |
| 36744538 | The significance of margins in pediatric Non-Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). | Cancer Med | 2023 |
| 36933012 | Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. | Acta Neuropathol | 2023 |
| 36542877 | Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. | Eur J Cancer | 2023 |
| 37364231 | Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | JCO Precis Oncol | 2023 |
| 36916248 | Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study. | Neuro Oncol | 2023 |
| 37856763 | Inflammatory Myofibroblastic Tumor With <i>ROS1</i> Gene Fusions in Children and Young Adolescents. | JCO Precis Oncol | 2023 |
| 37932833 | Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. | Acta Neuropathol Commun | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 37287693 | A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial <i>ZFTA-</i>fused ependymoma. | Neurooncol Adv | 2023 |
| 37085539 | 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma. | Nat Commun | 2023 |
| 37246777 | Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study. | Neuro Oncol | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37441736 | Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. | Clin Pharmacol Ther | 2023 |
| 37364231 | Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. | JCO Precis Oncol | 2023 |
| 37066598 | Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). | Pediatr Blood Cancer | 2023 |
| 36964296 | Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. | NPJ Precis Oncol | 2023 |
| 36916248 | Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study. | Neuro Oncol | 2023 |
| 36542877 | Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. | Eur J Cancer | 2023 |
| 36744538 | The significance of margins in pediatric Non-Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). | Cancer Med | 2023 |
| 36933012 | Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. | Acta Neuropathol | 2023 |
| 35018471 | SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study. | Neuro Oncol | 2022 |
| 35974385 | Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry. | J Hematol Oncol | 2022 |
| 35901835 | Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2022 |
| 35446794 | SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. | Am J Surg Pathol | 2022 |
| 35954372 | Adult Medulloblastoma: Updates on Current Management and Future Perspectives. | Cancers (Basel) | 2022 |
| 35745613 | Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. | Pharmaceuticals (Basel) | 2022 |
| 35490564 | The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium. | Eur J Cancer | 2022 |
| 35613412 | Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion. | JCO Precis Oncol | 2022 |
| 35728810 | Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. | Neuropathol Appl Neurobiol | 2022 |
| 35982066 | PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. | Sci Rep | 2022 |
| 35018471 | SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study. | Neuro Oncol | 2022 |
| 35163955 | Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices-A Practical Example. | Molecules | 2022 |
| 35158947 | The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. | Cancers (Basel) | 2022 |
| 35176224 | Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas. | Lancet Child Adolesc Health | 2022 |